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Serum Prolactin Levels in Behçet’s Disease.  
Is There a Relationship between Behcet’s Disease  
and Prolactin as in Other Autoimmune Diseases?
Behçet’s disease (BD) is a multi-system disorder 
(etiologically unknown) presenting with oral and gen-
ital aphthae, arthritis, cutaneous lesions, eye lesions 
and central nervous system involvement. Although 
found worldwide, it is mostly reported in Turkey and 
Japan, followed by Middle East and Mediterranean 
area as other regions according to its prevalence (1,2). 
Diagnosis is made clinically. In addition to recurrent 
aphthous ulceration, at least two symptoms of re-
current genital ulceration, typical eye lesions, typical 
dermatologic lesions, and positive pathergy test are 
needed for BD diagnosis. There is no specific labora-
tory test (3). In its etiology, many factors have been 
postulated, such as heredity, autoimmunity, infec-
tive agents and inflammatory mediators. BD tends to 
manifest in autoimmune disorders. Prolactin is a pre-
hypophysis hormone considered to be strongly relat-
ed to autoimmunity. Supported by many researches, 
prolactin can accompany the progress of some au-
toimmune diseases (systemic lupus erythematosus, 
uveitis, rheumatoid arthritis, multiple sclerosis, auto-
immune thyroiditis, psoriatic arthritis, etc.) and it can 
also arise in some autoimmune diseases. In the light of 
these ideas, we studied whether there is a relationship 
between BD and serum prolactin level, and compared 
it with similar studies reported in the literature.
Serum prolactin levels rise in many autoimmune 
diseases. Prolactin levels were determined in patients 
in active BD stage with dermatologic diagnosis but 
taking no therapy for the disease, in order to demon-
strate the relationship between BD, which has been 
increasingly defined as an autoimmune multisystem 
disease, and the level of serum prolactin, an immu-
nostimulating hormone of adenohypophysis; in ad-
dition, the results obtained were compared with lit-
erature data.
The study included 43 patients, 21 female and 22 
male, and 20 healthy age- and sex-matched subjects 
as control group. Patients in BD group were in the ac-
tive stage of the disease with manifest oral aphthae, 
genital aphthae, erythema nodosum and positivity 
for pathergy. In addition, arthralgia accompanied the 
disease in 20 patients. BD patients had not received 
any treatment for the past six months. In order to 
obviate the effect of sleep and food, blood samples 
were collected in fasting state, between 8.30 and 
10.30 a.m. Serum prolactin levels were measured on 
an Immulite 2004 device using the immunometric as-
say, with 3.0-20.0 ng/mL (female) and 2.5-17.0 ng/mL 
(male) accepted as normal values.
Study group included 43 BD patients, 21 (48.8%) 
female and 22 (51.2%) male. Control group had in-
cluded 20 healthy subjects, 11 (55%) female and 9 
(45%) male. There was no sex difference between the 
patient and control groups (p=0.941). The mean pro-
lactin level was 11.63 ng/mL in BD group and 10.19 
ng/mL in control group, yielding no significant be-
tween-group difference in the mean prolactin level 
(t=1.272; p=0.264). 
The mean serum prolactin level in BD patients was 
11.6 ng/mL; 9.84 ng/mL in female and 9.27 ng/mL in 
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male BD patients. The mean serum prolactin level 
in the healthy control group was 8.24 ng/mL; t-test 
produced no statistically significant difference be-
tween the BD patient group and control group. How-
ever, although there was no statistically significant 
difference, higher prolactin levels were measured 
in the group of BD patients as compared with con-
trol group. On the contrary, there are study reports 
on high serum prolactin levels in BD. In their study, 
Proença et al. from Portugal showed the mean serum 
prolactin levels to be significantly higher in BD pa-
tients as compared with control group (19.34ng/mL 
vs. 9.83 ng/mL) (4). Our results are similar to those re-
ported in the literature. However, additional studies 
are needed to clarify the issue. We believe that future 
in-depth research should identify these differences as 
being significant or nonsignificant.  
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Figure 1. Serum prolactin levels in Behcet’s disease and control groups.
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